ATTACKING DISEASE USING MACROPHAGE BIOLOGY

About Us

Mperia Therapeutics develops innovative macrophage-targeting immunotherapies via CD36 scavenger receptor. Lead peptide-based candidates have been identified in age-related macular degeneration (AMD) and atherosclerosis. Mperia explores new medical indications where chronic inflammation is clearly involved.

Twitter News

Twitter news